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Abstract
Symptomatic 𝛽-thalassemia is one of the globally most common inherited disorders. The initial
clinical presentation is variable. Although common hematological analyses are typically sufficient
to diagnose the disease, sometimes the diagnosis can be more challenging. We describe a series
of patients with 𝛽-thalassemia whose diagnosis was delayed, required bone marrow examination
in one affected member of each family, and revealed ringed sideroblasts, highlighting the associa-
tion of this morphological finding with these disorders. Thus, in the absence of characteristic con-
genital sideroblastic mutations or causes of acquired sideroblastic anemia, the presence of ringed
sideroblasts should raise the suspicion of 𝛽-thalassemia.
K EYWORDS
ringed sideroblasts, sideroblastic anemia, thalassemia
1 INTRODUCTION
Thalassemias and hemoglobinopathies are extremely common,
affecting hundreds of millions of individuals worldwide.1 𝛼- and
𝛽-Thalassemias are the inherited forms of anemia arising from
Abbreviations: MRI, magnetic resonance imaging; ROS, reactive oxygen species
defective synthesis of𝛼- or 𝛽-globin chains, respectively. 𝛽-Thalassemia
ranges in severity from asymptomatic conditions (heterozygous), tha-
lassemiaminor or trait, to severe transfusion-dependent forms termed
as thalassemiamajor. Phenotypes between these extremes are defined
as thalassemia intermedia, usually characterized by mild-to-moderate
anemia, transfusion independence, and iron overload.2,3 Complete
blood count parameters, hemoglobin electrophoresis, and globin chain
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mutation detection are typically sufficient to diagnose thalassemias.
The pathogenesis of 𝛽-thalassemia involves an excess of 𝛼-globin
compared to 𝛽-globin chain synthesis and/or stability that leads to
ineffective erythropoieisis and decreased red blood cell survival.
In some situations, particularly those associated with uncommon
𝛼-globin locus amplifications, even a molecular diagnosis can be
evasive. Here, we describe a series of thalassemia syndromes, for
which patients underwent bonemarrow sampling, and in which ringed
sideroblasts, the hallmark of another group of anemias—the siderob-
lastic anemias—were detected prior to the discovery of a genotype
diagnostic of 𝛽-thalassemia.
2 PATIENT DESCRIPTIONS
Patient 1 is a 34-year-oldmanwith a history of normo/macrocytic ane-
mia since birth (Fig. 1A). He was diagnosed with hemolytic anemia,
iron overload, and presumptive 𝛽-thalassemia trait (Table 1). He under-
went splenectomy and cholecystectomy during childhood. At the age
of 28, bone marrow examination showed occasional ringed siderob-
lasts. Congenital sideroblastic anemia (CSA) mutations were excluded
by sequencing.4 Copy number analysis using the Affimetrix 6.0 array
revealed aduplicationof∼179kbonchromosome16p (GRCh37/hg19;
chr16: 107,000–386,423) encompassing theentire𝛼-globin gene locus
and all or part of 10 other genes (Fig. 1D), resulting in four copies
of 𝛼-globin on this allele. No copy number alterations were detected
at the 𝛽-globin locus. HBB sequence analysis showed the common
𝛽-globin nonsensemutation, c.118C>T, p.Q40X (HVGSnomenclature);
codon39 (C>T); Gln>STP (HbVar nomenclature). Analysis of parental
samples demonstrated that the 𝛼-locus duplication and 𝛽-globinmuta-
tion were from his Irish mother and Italian father, respectively. These
findings indicate that he has 𝛽-thalassemia intermedia caused by het-
erozygous 𝛽-thalassemia trait and an 𝛼-chain excess. He has needed
blood transfusions only twice in his life: at the age of 9 for an aplas-
tic crisis due to parvovirus infection and at the age of 27 after carbon
monoxide poisoning. His current medications are deferasirox, for non-
transfusional iron overload and hydroxyurea, which ameliorates his
anemia.
Patient 2 is a 35-year-old woman, sister of patient 1. At the age of
2, she was found to have hemolytic anemia with macrocytosis. Like
her brother, she underwent splenectomy and cholecystectomy dur-
ing childhood. Molecular testing decades later revealed the same 𝛽-
globinmutationand𝛼-globin geneduplication.Although they share the
same genetic pattern, she has required many blood transfusions dur-
ing infections and her two pregnancies. Presently, she is not regularly
transfused and her current medications are deferasirox and hydrox-
yurea. Her last hepatic and cardiacmagnetic resonance imaging (MRIs)
were normal.
Patient 3 is a 17-year-old Greekmale of consanguineous parentage
with microcytic anemia since birth. At the age of 7, he was found to
have a heterozygous HBB c.315 + 1G>A (IVS-II-1 G>A) splicing muta-
tion. He underwent bone marrow examination twice because his ane-
mia severity was not explained by this molecular result. At the age of
7, many ringed sideroblasts were detected, while 4 years later they
were no longer visible. CSA mutations were excluded. At the age of
13, genetic testing identified an ∼140 kb duplication of the 𝛼-globin
locus and all or part of four contiguous genes (GRCh37/hg19; chr16:
110,690-253,576). This duplication is entirely within the region dupli-
cated inpatients 1 and2and, in combinationwith 𝛽-thalassemia trait, is
responsible for his severe anemia and ineffective erythropoiesis. Since
the age of 9, he has been regularly transfused and was on deferasirox
for iron overload.
Patient 4 is a 12-year-old female, sister of patient 3. She was diag-
nosed prenatally with 𝛽-thalassemia trait. She presented microcytic
anemia at birth. At the age of 9, she was found to share the same
genetic pattern as her brother. She is regularly transfused since the age
of 8 and is currently taking deferasirox with benefit.
Patient 5 is a 1-year-old female who was diagnosed with severe
microcytic anemia at the age of 2 months. At 8 months, bone mar-
row aspiration revealed the presence of numerous ringed sideroblasts
F IGURE 1 Siderocytes and ringed sideroblasts in patients with 𝛽-thalassemias. (A) Iron-stained peripheral blood smear from patient 1 demon-
strating hypochromic microcytic anemia with numerous nucleated RBCs and abundant sideroctyes. (B and C) Iron-stained bone marrow aspirates
frompatients 5 and 6, respectively, showing coarse perinuclear deposits of iron, typical of ringed sideroblasts. (D)Diagramof the 𝛼-globin locus and
flanking regions on human chromosome 16. Genes are indicated by black bars and regions duplicated in families 1 and 2 are indicated by gray bars.
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(Fig. 1B). Because of persistently elevated hemoglobin F (HbF) and
(retrospectively discovered) increased hemoglobin A2 in both parents,
testing forHBBmutationswas performed,which led to the diagnosis of
𝛽-thalassemia due to two 𝛽-globin splicingmutations: c.92+ 1G> [IVS-
I-1 (G>T)] and c.92+ 6T>C [IVS-I-6 (T>C)]. The first is a 𝛽0 allele, while
the second is the Portuguese-type 𝛽+-mutation that reduces the effi-
ciency of splicing at a 5′ splice donor site. She is regularly transfused
every 3–4weeks and is not yet on chelators given her young age. Liver
and cardiacMRI have not been performed.
Patient 6 is a 10-year-old Chinese female. At the age of 2, at
the time of adoption, a normocytic anemia of uncertain etiology was
detected and she was started on regular transfusions. Bone marrow
examination, repeated twice, demonstrated presence of ringed sider-
oblasts (Fig. 1C). At the age of 7, genetic testing was performed and
two 𝛽-globinmutationswere found: c.126_129delCTTT (p.F42LfsX19)
[codons 41/42 (-TTCT)] frameshift and c.316-197C>T (IVS II-654
C>T). Both of these severe 𝛽-thalassemia mutations are common in
China. She ismaintained on chronic transfusion and has been on chela-
tors since she was 5-year-old and her hepatic and cardiac MRIs are
normal.
Patient 7 is a Caucasian 6-year-old male diagnosed with chronic
normocytic anemia at the age of 1 year. At the age of 3, bone marrow
aspiration showed only erythroid hyperplasia. He started regular
transfusions and chelation at the age of 5. Bone marrow examination
was repeated at the age of 6 and revealed increased storage iron
and ringed sideroblasts. Research genetic testing excluded known
sideroblastic anemia mutations. Because of persistently elevated
HbF, HBB was sequenced and showed a novel 𝛽-globin mutation:
c.444A>C (p.X148YextX21 [beta stop codon STP>Tyr-Ala-Arg-Phe-
Leu-Ala-Val-Gln-Phe-Leu-Leu-Lys-Val-Pro-Leu-Phe-Pro-Lys-Ser-Asn-
Tyr-STP]), a stop-loss mutation. No abnormal hemoglobins were
detected on hemoglobin electrophoresis. Common 𝛼-globin tripli-
cations were excluded by genomic PCR.5 The exact mechanism(s)
whereby this and other C-terminal 𝛽-globin mutations cause anemia
is not always evident. The absence of variant peptide may indicate
an unstable protein variant leading to 𝛽-globin deficiency, while a
thalassemia-like loss of expression is also possible. Segregation analy-
sis demonstrated that this mutation was de novo, suggesting that the
phenotype is dominant. His hepaticMRI shows iron overload.
3 DISCUSSION
Wepresent a series of challenging thalassemia diagnoses. Unusual fea-
tures that contributed to the delay in diagnosis included presentation
at birth or early infancy (patients 1, 3, 4, and 5), macrocytosis (patients
1, 2, and 6), only one parent with 𝛽-thalassemia trait or 𝛽-globin muta-
tion by sequencing (patients 1, 2, 3, and 4), consanguinity and only
one demonstrable 𝛽-thalassemia allele, or absence of the abnormal
hemoglobin on routine electrophoresis (patient 7). Apart frompatients
2 and4,whowere ascertained as siblings, these patients hadbonemar-
row aspiration to better understand their anemia. In each case, ringed
sideroblasts were detected.
Ringed sideroblasts are erythroblasts with pathologic iron deposits
inmitochondria and can be found inCSAs,myelodysplastic syndromes,
myeloproliferative disorders, drug-induced anemia, and metabolic
abnormalities such as copper deficiency or alcoholism.6,7 They
typically result from defects in protoporphyrin synthesis, iron–sulfur
cluster biogenesis, or mitochondrial protein synthesis.8 Only one tha-
lassemia patient with ringed sideroblasts has been reported: a 5-year-
old Korean female with mild anemia and iron overload, heterozygous
for an initiation codonmissense 𝛽0 allele (c.2T>G [beta initiation codon
Met>Arg]).9 The presence of ringed sideroblasts in patients with 𝛽-
thalassemia is almost certainly underrecognizedbecausebonemarrow
examination is usually not required for the diagnosis. In addition, as
in patient 3, the presence of ringed sideroblasts may be transient. In
several of these cases, a clue to the proper diagnosis was an increase
in HbF, which is not typically seen at very high levels in CSA (M.D.F.,
unpublished observation).
In transfusion-dependent patients, iron overload develops after 1–
2 years of regular transfusions,10 but hemosiderosis is also present
in nontransfusion-dependent thalassemia patients, likely because ane-
mia and ineffective erythropoiesis cause suppression of hepcidin and
increased iron absorption.11,12 Iron toxicity fromhemosiderosis seems
to increase reactive oxygen species (ROS) in bone marrow,13–16 wors-
ening ineffective erythropoiesis by apoptosis induction. ROS damage
due to iron overload may be an explanation for impaired heme synthe-
sis or other mitochondrial defects, leading to sideroblasts production
in thalassemia, but further studies are needed to better understand
and characterize thesemechanisms.
Thalassemia is a commondisease, but occasionally thediagnosis can
be challenging. CSA is comparatively very rare. Based on our expe-
rience in nearly 200 individuals diagnosed with CSA based on bone
marrow findings, <3% have a 𝛽-thalassemia genotype. Nonetheless,
thesepatients highlight that ringed sideroblasts canbedetected in tha-
lassemic patients and in the absence of sideroblastic anemiamutations
or other known causes of ringed sideroblasts, their presence should
raise the suspicion of 𝛽-thalassemia.
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